-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
Ivermectin	B-I
as	O
a	O
Potential	O
Treatment	O
for	O
Mild	O
to	O
Moderate	O
COVID	O
-	O
19	O
:	O
A	O
Double	O
-	O
Blind	O
Randomized	O
Placebo	O
Controlled	O
Trial	O
in	O
Eastern	O
India	O
.	O

METHODS	O
:	O
A	O
double	O
blind	O
,	O
parallel	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
among	O
adult	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
disease	I-P
severity	I-P
on	I-P
admission	I-P
in	I-P
a	I-P
COVID	I-P
dedicated	I-P
tertiary	I-P
healthcare	I-P
of	I-P
eastern	I-P
India	I-P
.	O

Enrolment	O
was	O
done	O
between	O
1	O
st	O
August	O
and	O
31	O
st	O
October	O
2020	O
.	O

On	O
day	O
1	O
and	O
2	O
post	O
enrolment	O
,	O
patients	O
in	O
the	O
intervention	O
arm	O
received	O
ivermectin	B-I
12	O
mg	O
while	O
the	O
patients	O
in	O
the	O
non	O
-	O
interventional	O
arm	O
received	O
placebo	B-C
tablets	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Oral	B-I
Azithromycin	I-I
vs	O
Placebo	B-C
on	O
COVID	O
-	O
19	O
Symptoms	O
in	O
Outpatients	B-P
With	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
Infection	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
clinical	O
trial	O
of	O
azithromycin	B-I
vs	O
matching	B-C
placebo	I-C
conducted	O
from	O
May	O
2020	O
through	O
March	O
2021	O
.	O

Outpatients	B-P
from	I-P
the	I-P
US	I-P
were	O
enrolled	O
remotely	O
via	O
internet	O
-	O
based	O
surveys	O
and	O
followed	O
up	O
for	O
21	O
days	O
.	O

Eligible	O
participants	O
had	O
a	O
positive	O
SARS	O
-	O
CoV	O
-	O
2	O
diagnostic	O
test	O
result	O
(	O
nucleic	O
acid	O
amplification	O
or	O
antigen	O
)	O
within	O
7	O
days	O
prior	O
to	O
enrollment	O
,	O
were	O
aged	O
18	O
years	O
or	O
older	O
,	O
and	O
were	O
not	O
hospitalized	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Among	O
604	O
individuals	O
screened	O
,	O
297	O
were	O
ineligible	O
,	O
44	O
refused	O
participation	O
,	O
and	O
263	O
were	O
enrolled	O
.	O

Participants	O
,	O
investigators	O
,	O
and	O
study	O
staff	O
were	O
masked	O
to	O
treatment	O
randomization	O
.	O

Participants	O
were	O
randomized	O
in	O
a	O
2	O
:	O
1	O
fashion	O
to	O
a	B-I
single	I-I
oral	I-I
1	I-I
.	I-I
2	I-I
-	I-I
g	I-I
dose	I-I
of	I-I
azithromycin	I-I
(	O
n	O
=	O
171	O
)	O
or	O
matching	B-C
placebo	I-C
(	O
n	O
=	O
92	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
absence	B-O
of	I-O
self	I-O
-	I-O
reported	I-O
COVID	I-O
-	I-O
19	I-O
symptoms	I-O
at	O
day	O
14	O
.	O

There	O
were	O
23	O
secondary	O
clinical	O
end	O
points	O
,	O
including	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
at	O
day	O
21	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Canakinumab	B-I
vs	O
Placebo	B-C
on	O
Survival	O
Without	O
Invasive	O
Mechanical	O
Ventilation	O
in	O
Patients	B-P
Hospitalized	I-P
With	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
3	O
trial	O
was	O
conducted	O
at	O
39	O
hospitals	O
in	O
Europe	O
and	O
the	O
United	O
States	O
.	O

A	B-P
total	I-P
of	I-P
454	I-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
,	I-P
hypoxia	I-P
(	I-P
not	I-P
requiring	I-P
invasive	I-P
mechanical	I-P
ventilation	I-P
[	I-P
IMV	I-P
]	I-P
)	I-P
,	I-P
and	I-P
systemic	I-P
hyperinflammation	I-P
defined	I-P
by	I-P
increased	I-P
blood	I-P
concentrations	I-P
of	I-P
C	I-P
-	I-P
reactive	I-P
protein	I-P
or	I-P
ferritin	I-P
were	O
enrolled	O
between	O
April	O
30	O
and	O
August	O
17	O
,	O
2020	O
,	O
with	O
the	O
last	O
assessment	O
of	O
the	O
primary	O
end	O
point	O
on	O
September	O
22	O
,	O
2020	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
receive	O
a	B-I
single	I-I
intravenous	I-I
infusion	I-I
of	I-I
canakinumab	I-I
(	O
450	O
mg	O
for	O
body	O
weight	O
of	O
40	O
-	O
<	O
60	O
kg	O
,	O
600	O
mg	O
for	O
60	O
-	O
80	O
kg	O
,	O
and	O
750	O
mg	O
for	O
>	O
80	O
kg	O
;	O
n	O
=	O
227	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
227	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
survival	B-O
without	I-O
IMV	I-O
from	O
day	O
3	O
to	O
day	O
29	O
.	O

Secondary	O
outcomes	O
were	O
COVID	B-O
-	I-O
19	I-O
-	I-O
related	I-O
mortality	I-O
,	O
measurements	B-O
of	I-O
biomarkers	I-O
of	I-O
systemic	I-O
hyperinflammation	I-O
,	O
and	O
safety	B-O
evaluations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Dapagliflozin	B-I
in	O
patients	B-P
with	I-P
cardiometabolic	I-P
risk	I-P
factors	I-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
DARE	O
-	O
19	O
)	O
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
DARE	O
-	O
19	O
was	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
patients	B-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
with	I-P
at	I-P
least	I-P
one	I-P
cardiometabolic	I-P
risk	I-P
factor	I-P
(	I-P
ie	I-P
,	I-P
hypertension	I-P
,	I-P
type	I-P
2	I-P
diabetes	I-P
,	I-P
atherosclerotic	I-P
cardiovascular	I-P
disease	I-P
,	I-P
heart	I-P
failure	I-P
,	I-P
and	I-P
chronic	I-P
kidney	I-P
disease	I-P
)	I-P
.	O

Patients	O
critically	O
ill	O
at	O
screening	O
were	O
excluded	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
dapagliflozin	B-I
(	O
10	O
mg	O
daily	O
orally	O
)	O
or	O
matched	B-C
placebo	I-C
for	O
30	O
days	O
.	O

Dual	O
primary	O
outcomes	O
were	O
assessed	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
:	O
the	B-O
outcome	I-O
of	I-O
prevention	I-O
(	O
time	B-O
to	I-O
new	I-O
or	O
worsened	B-O
organ	I-O
dysfunction	I-O
or	O
death	B-O
)	O
,	O
and	O
the	B-O
hierarchial	I-O
composite	I-O
outcome	I-O
of	I-O
recovery	I-O
(	O
change	O
in	O
clinical	B-O
status	I-O
by	O
day	O
30	O
)	O
.	O

Safety	B-O
outcomes	I-O
,	O
in	O
patients	O
who	O
received	O
at	O
least	O
one	O
study	O
medication	O
dose	O
,	O
included	O
serious	B-O
adverse	I-O
events	I-O
,	O
adverse	B-O
events	I-O
leading	I-O
to	I-O
discontinuation	I-O
,	O
and	O
adverse	B-O
events	I-O
of	I-O
interest	I-O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04350593	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Brazilian	B-I
green	I-I
propolis	I-I
(	O
EPP	B-I
-	I-I
AF	I-I
)	O
as	O
an	O
adjunct	O
treatment	O
for	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
A	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
trial	O
,	O
hospitalized	B-P
adult	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
treated	O
with	O
a	B-I
standardized	I-I
green	I-I
propolis	I-I
extract	I-I
(	O
EPP	B-I
-	I-I
AF?	I-I
)	O
as	O
an	O
adjunct	O
therapy	O
.	O

Patients	O
were	O
allocated	O
to	O
receive	O
standard	B-I
care	I-I
plus	O
an	B-I
oral	I-I
dose	I-I
of	I-I
400	I-I
mg	I-I
or	O
800	B-I
mg	I-I
/	I-I
day	I-I
of	I-I
green	I-I
propolis	I-I
for	O
seven	O
days	O
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

Standard	B-I
care	I-I
included	O
all	O
necessary	O
interventions	O
,	O
as	O
determined	O
by	O
the	O
attending	O
physician	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
time	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
defined	O
as	O
the	B-O
length	I-O
of	I-O
hospital	I-O
stay	I-O
or	O
oxygen	B-O
therapy	I-O
dependency	I-O
duration	I-O
.	O

Secondary	O
outcomes	O
included	O
acute	B-O
kidney	I-O
injury	I-O
and	O
need	B-O
for	I-O
intensive	I-O
care	I-O
or	O
vasoactive	B-O
drugs	I-O
.	O

Patients	O
were	O
followed	O
for	O
28	O
days	O
after	O
admission	O
.	O

-DOCSTART-	O

Title	O
:	O
Doxycycline	B-I
for	O
community	O
treatment	O
of	O
suspected	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
high	I-P
risk	I-P
of	I-P
adverse	I-P
outcomes	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
national	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
adaptive	O
platform	O
randomised	O
trial	O
of	O
interventions	O
against	O
COVID	O
-	O
19	O
in	O
older	O
people	O
(	O
PRINCIPLE	O
)	O
across	O
primary	O
care	O
centres	O
in	O
the	O
UK	O
.	O

We	O
included	O
people	B-P
aged	I-P
65	I-P
years	I-P
or	I-P
older	I-P
,	I-P
or	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
comorbidities	I-P
(	I-P
weakened	I-P
immune	I-P
system	I-P
,	I-P
heart	I-P
disease	I-P
,	I-P
hypertension	I-P
,	I-P
asthma	I-P
or	I-P
lung	I-P
disease	I-P
,	I-P
diabetes	I-P
,	I-P
mild	I-P
hepatic	I-P
impairment	I-P
,	I-P
stroke	I-P
or	I-P
neurological	I-P
problem	I-P
,	I-P
and	I-P
self	I-P
-	I-P
reported	I-P
obesity	I-P
or	I-P
body	I-P
-	I-P
mass	I-P
index	I-P
of	I-P
35	I-P
kg	I-P
/	I-P
m2	I-P
or	I-P
greater	I-P
)	I-P
,	I-P
who	I-P
had	I-P
been	I-P
unwell	I-P
(	I-P
for	I-P
?14	I-P
days	I-P
)	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
or	I-P
a	I-P
positive	I-P
PCR	I-P
test	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
in	I-P
the	I-P
community	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
using	O
response	O
adaptive	O
randomisation	O
to	O
usual	B-C
care	I-C
only	I-C
,	O
usual	B-I
care	I-I
plus	O
oral	B-I
doxycycline	I-I
(	O
200	O
mg	O
on	O
day	O
1	O
,	O
then	O
100	O
mg	O
once	O
daily	O
for	O
the	O
following	O
6	O
days	O
)	O
,	O
or	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
.	O

The	O
interventions	O
reported	O
in	O
this	O
manuscript	O
are	O
usual	B-I
care	I-I
plus	O
doxycycline	B-I
and	O
usual	B-C
care	I-C
only	I-C
;	O
evaluations	O
of	O
other	O
interventions	O
in	O
this	O
platform	O
trial	O
are	O
ongoing	O
.	O

The	O
coprimary	O
endpoints	O
were	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
,	O
and	O
hospitalisation	B-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
both	O
measured	O
over	O
28	O
days	O
from	O
randomisation	O
and	O
analysed	O
by	O
intention	O
to	O
treat	O
.	O

This	O
trial	O
is	O
ongoing	O
and	O
is	O
registered	O
with	O
ISRCTN	O
,	O
86534580	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	O
Anticoagulation	O
with	O
Heparin	B-I
in	O
Noncritically	B-P
Ill	I-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
open	O
-	O
label	O
,	O
adaptive	O
,	O
multiplatform	O
,	O
controlled	O
trial	O
,	O
we	O
randomly	O
assigned	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
and	I-P
who	I-P
were	I-P
not	I-P
critically	I-P
ill	I-P
(	I-P
which	I-P
was	I-P
defined	I-P
as	I-P
an	I-P
absence	I-P
of	I-P
critical	I-P
care	I-P
-	I-P
level	I-P
organ	I-P
support	I-P
at	I-P
enrollment	I-P
)	I-P
to	O
receive	O
pragmatically	O
defined	O
regimens	O
of	O
either	O
therapeutic	B-I
-	I-I
dose	I-I
anticoagulation	I-I
with	I-I
heparin	I-I
or	O
usual	B-C
-	I-C
care	I-C
pharmacologic	I-C
thromboprophylaxis	I-C
.	O

The	O
primary	O
outcome	O
was	O
organ	B-O
support	I-O
-	I-O
free	I-O
days	I-O
,	O
evaluated	O
on	O
an	B-O
ordinal	I-O
scale	I-O
that	O
combined	O
in	B-O
-	I-O
hospital	I-O
death	I-O
(	O
assigned	O
a	O
value	O
of	O
-	O
1	O
)	O
and	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
cardiovascular	I-O
or	O
respiratory	B-O
organ	I-O
support	I-O
up	O
to	O
day	O
21	O
among	O
patients	O
who	O
survived	O
to	O
hospital	O
discharge	O
.	O

This	O
outcome	O
was	O
evaluated	O
with	O
the	O
use	O
of	O
a	O
Bayesian	O
statistical	O
model	O
for	O
all	O
patients	O
and	O
according	O
to	O
the	O
baseline	O
d	O
-	O
dimer	O
level	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
Humanoid	I-I
Robot	I-I
Sil	I-I
-	I-I
Bot	I-I
in	I-I
a	I-I
Cognitive	I-I
Training	I-I
Program	I-I
for	O
Community	B-P
-	I-P
Dwelling	I-P
Elderly	I-P
People	I-P
with	I-P
Mild	I-P
Cognitive	I-P
Impairment	I-P
during	I-P
the	I-P
COVID	I-P
-	I-P
19	I-P
Pandemic	I-P
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
with	O
135	B-P
volunteers	I-P
without	I-P
cognitive	I-P
impairment	I-P
aged	I-P
60	I-P
years	I-P
old	I-P
or	I-P
older	I-P
.	O

Participants	O
were	O
first	O
randomized	O
into	O
two	O
groups	O
.	O

One	O
group	O
consisted	O
of	O
90	O
participants	O
who	O
would	O
receive	O
cognitive	B-I
training	I-I
and	O
45	O
who	O
would	O
not	O
receive	O
any	B-C
training	I-C
(	I-C
NI	I-C
)	I-C
.	O

The	B-I
cognitive	I-I
training	I-I
group	O
was	O
randomly	O
divided	O
into	O
two	O
groups	O
,	O
45	O
who	O
received	O
traditional	B-C
cognitive	I-C
training	I-C
(	I-C
TCT	I-C
)	I-C
and	O
45	O
who	O
received	O
robot	B-I
-	I-I
assisted	I-I
cognitive	I-I
training	I-I
(	I-I
RACT	I-I
)	I-I
.	O

The	O
training	O
for	O
both	O
groups	O
consisted	O
of	O
a	O
daily	O
60	O
min	O
session	O
,	O
twice	O
a	O
week	O
for	O
six	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
convalescent	B-I
plasma	I-I
for	O
treatment	O
of	O
COVID	O
-	O
19	O
in	O
Uganda	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
a	I-P
positive	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
reverse	I-P
transcriptase	I-P
(	I-P
RT	I-P
)	I-P
-	I-P
PCR	I-P
test	I-P
irrespective	I-P
of	I-P
disease	I-P
severity	I-P
were	O
hospitalised	O
and	O
randomised	O
to	O
receive	O
either	O
COVID	B-I
-	I-I
19	I-I
CCP	I-I
plus	O
standard	B-I
of	I-I
care	I-I
(	I-I
SOC	I-I
)	I-I
or	O
SOC	B-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
viral	I-O
clearance	I-O
,	O
defined	O
as	O
having	B-O
two	I-O
consecutive	I-O
RT	I-O
-	I-O
PCR	I-O
-	I-O
negative	I-O
tests	I-O
by	O
day	O
28	O
.	O

Secondary	O
outcomes	O
included	O
time	B-O
to	I-O
symptom	I-O
resolution	I-O
,	O
clinical	B-O
status	I-O
on	O
the	B-O
modified	I-O
WHO	I-O
Ordinal	I-O
Clinical	I-O
Scale	I-O
(	O
?1	O
-	O
point	O
increase	O
)	O
,	O
progression	B-O
to	I-O
severe	I-O
/	I-O
critical	I-O
condition	I-O
(	O
defined	O
as	O
oxygen	B-O
saturation	I-O
<	I-O
93	I-O
%	I-O
or	O
needing	B-O
oxygen	I-O
)	O
,	O
mortality	B-O
and	O
safety	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Inhaled	B-I
budesonide	I-I
for	O
COVID	B-P
-	I-P
19	I-P
in	I-P
people	I-P
at	I-P
high	I-P
risk	I-P
of	I-P
complications	I-P
in	I-P
the	I-P
community	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
PRINCIPLE	O
is	O
a	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
randomised	O
,	O
controlled	O
,	O
adaptive	O
platform	O
trial	O
done	O
remotely	O
from	O
a	O
central	O
trial	O
site	O
and	O
at	O
primary	O
care	O
centres	O
in	O
the	O
UK	O
.	O

Eligible	O
participants	O
were	O
aged	B-P
65	I-P
years	I-P
or	I-P
older	I-P
or	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
comorbidities	I-P
,	I-P
and	I-P
unwell	I-P
for	I-P
up	I-P
to	I-P
14	I-P
days	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
but	I-P
not	I-P
admitted	I-P
to	I-P
hospital	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
usual	B-C
care	I-C
,	O
usual	B-I
care	I-I
plus	O
inhaled	B-I
budesonide	I-I
(	O
800	O
?g	O
twice	O
daily	O
for	O
14	O
days	O
)	O
,	O
or	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
,	O
and	O
followed	O
up	O
for	O
28	O
days	O
.	O

Participants	O
were	O
aware	O
of	O
group	O
assignment	O
.	O

The	O
coprimary	O
endpoints	O
are	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
and	O
hospital	B-O
admission	I-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
within	O
28	O
days	O
,	O
analysed	O
using	O
Bayesian	O
models	O
.	O

The	O
primary	O
analysis	O
population	O
included	O
all	O
eligible	O
SARS	O
-	O
CoV	O
-	O
2	O
-	O
positive	O
participants	O
randomly	O
assigned	O
to	O
budesonide	B-I
,	O
usual	B-C
care	I-C
,	O
and	O
other	B-I
interventions	I-I
,	O
from	O
the	O
start	O
of	O
the	O
platform	O
trial	O
until	O
the	B-I
budesonide	I-I
group	O
was	O
closed	O
.	O

This	O
trial	O
is	O
registered	O
at	O
the	O
ISRCTN	O
registry	O
(	O
ISRCTN86534580	O
)	O
and	O
is	O
ongoing	O
.	O

-DOCSTART-	O

Title	O
:	O
Nature	O
and	O
Dimensions	O
of	O
Systemic	O
Hyperinflammation	O
and	O
its	O
Attenuation	O
by	O
Convalescent	B-I
Plasma	I-I
in	O
Severe	O
COVID	O
-	O
19	O
.	O

METHODS	O
:	O
First	O
,	O
to	O
characterize	O
key	O
cytokines	O
and	O
their	O
dynamics	O
in	O
this	O
hyperinflammatory	O
condition	O
,	O
we	O
assessed	O
abundance	O
and	O
correlative	O
expression	O
of	O
a	O
panel	O
of	O
48	O
cytokines	O
in	O
patients	B-P
progressing	I-P
to	I-P
ARDS	I-P
as	I-P
compared	I-P
to	I-P
patients	I-P
with	I-P
mild	I-P
disease	I-P
.	O

Then	O
,	O
in	O
an	O
ongoing	O
randomized	O
controlled	O
trial	O
of	O
convalescent	B-I
plasma	I-I
therapy	I-I
(	I-I
CPT	I-I
)	I-I
,	O
we	O
analyzed	O
rapid	O
effects	O
of	O
CPT	B-I
on	O
the	O
systemic	B-O
cytokine	I-O
dynamics	I-O
as	O
a	O
correlate	O
for	O
the	B-O
level	I-O
of	I-O
hypoxia	I-O
experienced	I-O
by	I-O
the	I-O
patients	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Combined	O
use	O
of	O
a	B-I
broad	I-I
-	I-I
panel	I-I
respiratory	I-I
multiplex	I-I
PCR	I-I
and	O
procalcitonin	B-I
to	O
reduce	O
duration	O
of	O
antibiotics	O
exposure	O
in	O
patients	B-P
with	I-P
severe	I-P
community	I-P
-	I-P
acquired	I-P
pneumonia	I-P
(	O
MULTI	O
-	O
CAP	O
)	O
:	O
a	O
multicentre	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
individual	O
randomised	O
trial	O
conducted	O
in	O
French	O
intensive	O
care	O
units	O
.	O

METHODS	O
:	O
The	B-I
multiplex	I-I
PCR	I-I
and	O
procalcitonin	B-I
to	O
reduce	O
duration	O
of	O
antibiotics	O
exposure	O
in	O
patients	B-P
with	I-P
severe	I-P
-	I-P
CAP	I-P
(	I-P
MULTI	I-P
-	I-P
CAP	I-P
)	I-P
trial	I-P
is	O
a	O
multicentre	O
(	O
n=20	O
)	O
,	O
parallel	O
-	O
group	O
,	O
superiority	O
,	O
open	O
-	O
label	O
,	O
randomised	O
trial	O
.	O

Patients	O
are	O
included	O
if	O
adult	B-P
admitted	I-P
to	I-P
intensive	I-P
care	I-P
unit	I-P
for	I-P
a	I-P
CAP	I-P
.	O

Diagnosis	O
of	O
pneumonia	O
is	O
based	O
on	O
clinical	O
criteria	O
and	O
a	O
newly	O
appeared	O
parenchymal	O
infiltrate	O
.	O

Immunocompromised	O
patients	O
are	O
excluded	O
.	O

Subjects	O
are	O
randomised	O
(	O
1	O
:	O
1	O
ratio	O
)	O
to	O
either	O
the	O
intervention	O
arm	O
(	O
experimental	B-I
strategy	I-I
)	O
or	O
the	O
control	O
arm	O
(	O
usual	B-C
strategy	I-C
)	O
.	O

In	O
the	O
intervention	O
arm	O
,	O
the	B-I
microbiological	I-I
diagnosis	I-I
combines	O
a	B-I
respiratory	I-I
multiplex	I-I
PCR	I-I
(	I-I
mPCR	I-I
)	I-I
and	O
conventional	B-I
microbiological	I-I
investigations	I-I
.	O

An	O
algorithm	O
of	O
early	O
antibiotic	O
de	O
-	O
escalation	O
or	O
discontinuation	O
is	O
recommended	O
,	O
based	O
on	O
mPCR	O
results	O
and	O
the	O
procalcitonin	O
value	O
.	O

In	O
the	O
control	O
arm	O
,	O
only	O
conventional	B-C
microbiological	I-C
investigations	I-C
are	O
performed	O
and	O
antibiotics	O
de	O
-	O
escalation	O
remains	O
at	O
the	O
clinician	O
'	O
s	O
discretion	O
.	O

The	O
primary	O
endpoint	O
is	O
the	B-O
number	I-O
of	I-O
days	I-O
alive	I-O
without	I-O
any	I-O
antibiotic	I-O
from	O
the	O
randomisation	O
to	O
day	O
28	O
.	O

Based	O
on	O
our	O
hypothesis	O
of	O
2	O
days	O
gain	O
in	O
the	O
intervention	O
arm	O
,	O
we	O
aim	O
to	O
enrol	O
a	O
total	O
of	O
450	O
patients	O
over	O
a	O
30	O
-	O
month	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
two	B-I
siddha	I-I
polyherbal	I-I
decoctions	I-I
,	O
Nilavembu	B-I
Kudineer	I-I
and	O
Kaba	B-I
Sura	I-I
Kudineer	I-I
,	O
along	O
with	O
standard	B-I
allopathy	I-I
treatment	I-I
in	O
the	O
management	O
of	O
mild	B-P
to	I-P
moderate	I-P
symptomatic	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
-	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
comparative	O
clinical	O
trial	O
,	O
with	O
the	O
primary	O
objective	O
of	O
determining	O
the	O
efficacy	O
of	O
KSK	B-I
and	O
NVK	B-I
.	O

Patients	B-P
(	I-P
n=125	I-P
)	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
were	O
enrolled	O
in	O
the	O
study	O
over	O
a	O
period	O
of	O
4	O
months	O
(	O
Aug	O
2020	O
-	O
Dec	O
2020	O
)	O
.	O

Participants	O
were	O
randomized	O
into	O
3	O
arms	O
;	O
placebo	B-C
-	O
decaffeinated	B-C
tea	I-C
in	O
Arm	O
I	O
,	O
NVK	B-I
in	O
Arm	O
II	O
,	O
and	O
KSK	B-I
in	O
Arm	O
III	O
.	O

Each	O
arm	O
received	O
60	O
ml	O
of	O
the	O
respective	O
treatment	O
twice	O
a	O
day	O
,	O
post	O
morning	O
and	O
evening	O
meals	O
,	O
along	O
with	O
standard	B-I
allopathy	I-I
treatment	I-I
for	O
a	O
maximum	O
of	O
10	O
days	O
.	O

The	O
main	O
outcome	O
measures	O
of	O
the	O
study	O
were	O
the	O
reduction	O
in	O
SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
viral	I-O
load	I-O
,	O
hospital	B-O
stay	I-O
,	O
and	O
time	B-O
taken	I-O
by	I-O
the	I-O
patients	I-O
to	I-O
become	I-O
asymptomatic	I-O
from	I-O
symptomatic	I-O
.	O

Efficacy	O
assessments	O
included	O
clinical	B-O
symptoms	I-O
(	O
fever	B-O
,	O
cough	B-O
,	O
and	O
breathlessness	B-O
)	O
each	O
day	O
and	O
real	B-O
-	I-O
time	I-O
reverse	I-O
transcription	I-O
-	I-O
polymerase	I-O
chain	I-O
reaction	I-O
(	I-O
RT	I-O
-	I-O
PCR	I-O
)	I-O
,	O
liver	B-O
function	I-O
test	I-O
(	I-O
LFT	I-O
)	I-O
,	O
renal	B-O
function	I-O
test	I-O
(	I-O
RFT	I-O
)	I-O
,	O
and	O
electrolytes	B-O
and	I-O
electrocardiogram	I-O
(	I-O
ECG	I-O
)	I-O
at	O
baseline	O
(	O
day	O
0	O
)	O
and	O
days	O
3	O
,	O
6	O
,	O
and	O
10	O
.	O

Post	O
-	O
treatment	O
,	O
participants	O
were	O
followed	O
up	O
for	O
30	O
days	O
via	O
phone	O
for	O
adverse	O
effects	O
if	O
any	O
.	O

Effects	O
of	O
drugs	O
on	O
inflammatory	B-O
markers	I-O
(	O
IL6	B-O
)	O
at	O
the	O
end	O
of	O
treatment	O
were	O
also	O
recorded	O
.	O

Adverse	B-O
events	I-O
(	I-O
AE	I-O
)	I-O
were	O
monitored	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Metoprolol	B-I
in	O
Critically	B-P
Ill	I-P
Patients	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
20	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
with	I-P
ARDS	I-P
on	I-P
invasive	I-P
mechanical	I-P
ventilation	I-P
were	O
randomized	O
to	O
metoprolol	B-I
(	O
15	O
mg	O
daily	O
for	O
3	O
days	O
)	O
or	O
control	O
(	O
no	B-C
treatment	I-C
)	O
.	O

All	O
patients	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
before	O
and	O
after	O
metoprolol	B-I
/	O
control	O
.	O

The	O
safety	O
of	O
metoprolol	B-I
administration	O
was	O
evaluated	O
by	O
invasive	B-O
hemodynamic	I-O
and	O
electrocardiogram	B-O
monitoring	I-O
and	O
echocardiography	B-O
.	O

-DOCSTART-	O

Title	O
:	O
In	O
vivo	O
evaluation	O
of	O
the	O
virucidal	O
efficacy	O
of	O
chlorhexidine	B-I
and	O
povidone	B-I
-	O
iodine	B-I
mouthwashes	I-I
against	O
salivary	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

A	O
randomized	O
-	O
controlled	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
-	O
controlled	O
clinical	O
trial	O
,	O
studied	O
group	O
comprised	O
laboratory	B-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
positive	I-P
patients	I-P
through	I-P
nasopharyngeal	I-P
swabs	I-P
.	O

Participants	O
were	O
divided	O
into	O
3	O
groups	O
.	O

For	O
30	O
s	O
,	O
the	O
control	O
group	O
mouthrinsed	O
with	O
distilled	B-C
water	I-C
,	O
the	B-I
Chlorhexidine	I-I
group	O
mouthrinsed	O
with	O
0	B-I
.	I-I
2	I-I
%	I-I
Chlorhexidine	I-I
and	O
the	B-I
Povidone	I-I
-	O
iodine	B-I
group	O
gargled	O
with	O
1	B-I
%	I-I
Povidone	I-I
-	O
iodine	B-I
.	O

Saliva	O
samples	O
were	O
collected	O
before	O
and	O
5	O
min	O
after	O
mouthwash	O
.	O

SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
rRT	I-O
-	I-O
PCR	I-O
was	O
then	O
performed	O
for	O
each	O
sample	O
.	O

Evaluation	O
of	O
the	O
efficacy	O
was	O
based	O
on	O
difference	O
in	O
cycle	B-O
threshold	I-O
(	I-O
Ct	I-O
)	I-O
value	I-O
.	O

The	O
analysis	O
of	O
data	O
was	O
carried	O
out	O
using	O
GraphPad	O
Prism	O
version	O
5	O
for	O
Windows	O
.	O

Kristal	O
wullis	O
and	O
Paired	O
t	O
-	O
test	O
were	O
used	O
.	O

A	O
probability	O
value	O
of	O
less	O
than	O
0	O
.	O
05	O
was	O
regarded	O
as	O
statistically	O
significant	O
.	O

